SHBG (Extended) Interpretation by Decade of Life

What Is SHBG (Extended) and Why Does the "Extended" Panel Matter?

The standard SHBG test reports one number: total sex hormone-binding globulin in nmol/L. The extended panel goes further. It uses your measured SHBG, total testosterone, and a fixed albumin assumption of 4.3 g/dL to calculate free testosterone via the Vermeulen equation, which was validated in a 1999 paper in the Journal of Clinical Endocrinology and Metabolism that remains the reference method today [1].

What the Extended Panel Reports

The extended report typically includes:

• Total SHBG (nmol/L)
• Calculated free testosterone (pg/mL or pmol/L)
• Calculated free estradiol (pmol/L) when estradiol is drawn concurrently
• Percent free testosterone

Free testosterone represents roughly 1 to 3% of total testosterone in men and a smaller fraction in women. Because SHBG binds testosterone with roughly 10 times the affinity of albumin [1], even modest shifts in SHBG produce disproportionate changes in the bioavailable fraction.

Why Total Testosterone Alone Misleads

Consider two men, both with total testosterone at 500 ng/dL. One has SHBG at 20 nmol/L and a calculated free testosterone of 14 pg/mL. The other has SHBG at 65 nmol/L and a free testosterone of 7 pg/mL. The second man has half the active hormone despite an identical total. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy notes that "measurement of free testosterone by equilibrium dialysis or calculation using the Vermeulen equation is recommended when total testosterone results are not consistent with clinical presentation" [2].

How SHBG Changes Across the Lifespan

SHBG is not static. It tracks age, metabolic health, liver function, thyroid status, and exogenous hormone use. Understanding the trajectory is the foundation of decade-specific interpretation.

In Men

In healthy young adult men (ages 20 to 30), SHBG typically runs between 15 and 45 nmol/L [3]. A large cross-sectional analysis of the European Male Ageing Study (N=3,369) found that SHBG increased by approximately 1.6% per year after age 40, independent of changes in total testosterone [4]. By the seventh and eighth decades, median SHBG in men often exceeds 50 nmol/L, which is one reason free testosterone declines more steeply than total testosterone with age.

In Women

In premenopausal women, SHBG oscillates across the menstrual cycle, peaking near ovulation under the influence of rising estradiol, and ranges from roughly 30 to 130 nmol/L depending on cycle phase and assay [5]. Oral contraceptives containing ethinyl estradiol raise SHBG dramatically, sometimes tripling baseline levels, which can persist for months after discontinuation, a phenomenon documented in a 2006 study in the Journal of Sexual Medicine [6]. After menopause, SHBG tends to stabilize or decline modestly as estradiol falls, though individual variation is large.

SHBG Reference Ranges and Optimal Targets by Decade

Reference ranges describe a statistical population. Optimal ranges describe a clinical target. The two are not the same. The table below draws on published normative data from multiple cohort studies.

Men: Decade-by-Decade Targets

| Age Decade | Typical Population Range (nmol/L) | Longevity-Medicine Optimal Target (nmol/L) | |---|---|---| | 20s | 15 to 45 | 20 to 40 | | 30s | 15 to 48 | 20 to 45 | | 40s | 18 to 55 | 22 to 50 | | 50s | 22 to 62 | 25 to 55 | | 60s | 28 to 72 | 28 to 58 | | 70+ | 35 to 85 | 30 to 65 |

The Osteoporotic Fractures in Men (MrOS) study (N=1,563) found that men in the highest SHBG quartile had significantly lower free testosterone and higher rates of sexual dysfunction and low bone density compared with men in the middle two quartiles [3]. A value of 70 nmol/L in a 35-year-old man is not "normal aging." It demands investigation.

Women: Decade-by-Decade Targets

| Age Decade | Typical Population Range (nmol/L) | Clinical Notes | |---|---|---| | 20s, 30s (premenopausal) | 30 to 130 | Cycle-phase dependent; OCP use raises this dramatically | | 40s (perimenopause) | 25 to 100 | Declining estradiol reduces SHBG stimulus | | 50s+ (postmenopause) | 20 to 80 | Transdermal HRT has minimal impact; oral estrogen raises SHBG significantly |

The Women's Health Initiative Observational Study found that oral conjugated equine estrogen raised SHBG by 45 to 100% from baseline, whereas transdermal estradiol produced no statistically significant change [7]. This distinction directly affects free testosterone and free estradiol calculations in women on hormone therapy.

Interpreting a Low SHBG Result

Low SHBG (below 20 nmol/L in men, below 25 nmol/L in premenopausal women) is almost never benign when the clinical picture is considered.

Metabolic Drivers of Low SHBG

Insulin suppresses hepatic SHBG synthesis. A 2010 genome-wide association study published in the New England Journal of Medicine identified SHBG gene variants strongly linked to type 2 diabetes risk, suggesting that low SHBG is not merely a consequence of insulin resistance but may be mechanistically involved in its development [8]. The Nurses' Health Study (N=32,826) found that women in the lowest SHBG quintile had a relative risk of 2.7 for developing type 2 diabetes over 10 years compared with women in the highest quintile [9].

Practically, a man in his 30s with SHBG at 12 nmol/L almost certainly has one or more of the following: visceral obesity, elevated fasting insulin, non-alcoholic fatty liver disease, hypothyroidism, or exogenous androgen use. Treating the SHBG number without addressing these drivers produces limited durable benefit.

Low SHBG and Cardiovascular Risk

Low SHBG correlates with higher circulating free estrogens and androgens, greater triglyceride levels, and lower HDL cholesterol. A meta-analysis published in Diabetes Care (16 prospective cohorts, N=40,517) found that each 1-standard-deviation decrease in log SHBG was associated with a 20 to 25% increased risk of incident type 2 diabetes [10]. The American Heart Association's 2023 scientific statement on sex hormones and cardiovascular disease notes that "low SHBG, independent of sex steroid levels, may represent a biomarker of cardiometabolic risk" [11].

Low SHBG in Men on TRT

Men receiving testosterone replacement therapy often see SHBG fall as exogenous androgen suppresses SHBG synthesis. A SHBG below 15 nmol/L during TRT in a man with visceral obesity may indicate over-treatment or an underlying metabolic issue. Dosing frequency adjustments, switching from weekly to twice-weekly injections, or addressing insulin resistance can shift SHBG back into range [2].

Interpreting a High SHBG Result

High SHBG reduces bioavailable hormone. In the context of hormone optimization, this is often the more clinically pressing problem.

Causes of Elevated SHBG

The most common reversible causes in outpatient practice include:

• Hyperthyroidism (thyroid hormones directly stimulate hepatic SHBG synthesis)
• Oral estrogen use (including oral contraceptives and oral HRT)
• Significant caloric restriction or low BMI
• Chronic liver disease with preserved synthetic function (cirrhosis paradoxically lowers SHBG via synthetic failure)
• Aging, particularly in men over 60

A 2013 analysis from the Massachusetts Male Aging Study confirmed that SHBG elevation in older men is driven partly by decreased metabolic clearance rather than increased production alone [12].

High SHBG Masking Testosterone Deficiency

The Endocrine Society guideline (2018) explicitly states: "In men with SHBG concentrations outside the normal range, total testosterone alone may not reliably reflect androgen status" [2]. A 65-year-old man with total testosterone at 420 ng/dL (considered "normal" by most lab reference ranges) but SHBG at 75 nmol/L may have a free testosterone of only 5.5 pg/mL, which falls well below the functional threshold of 6.5 to 7 pg/mL used by many hormone specialists.

High SHBG in Women

Persistently elevated SHBG in premenopausal women, particularly values above 120 nmol/L, may explain low libido, poor genital sensitivity, or difficulty with arousal even when total testosterone appears adequate [5]. Switching from oral to transdermal or vaginal hormonal contraception is often the first clinical step, given the well-documented difference in hepatic first-pass effect.

SHBG and Free Testosterone: The Vermeulen Calculation in Practice

The Vermeulen equation calculates free testosterone as follows, using molar concentrations:

Free T (nmol/L) = Total T / (1 + Ka-albumin × [albumin] + Ka-SHBG × [SHBG])

Where Ka-SHBG is approximately 5.97 × 10^8 L/mol and Ka-albumin is approximately 3.6 × 10^4 L/mol [1]. Most extended SHBG panels perform this calculation automatically. The Endocrine Society recommends the Vermeulen method when direct free testosterone by equilibrium dialysis is unavailable, which is most outpatient settings [2].

Practical Free Testosterone Thresholds

Based on normative data from the European Male Ageing Study and the Framingham Heart Study testosterone substudy, the following calculated free testosterone thresholds are widely referenced:

• Men: symptomatic hypogonadism threshold approximately 6.5 pg/mL (225 pmol/L)
• Men: optimal functional range approximately 8 to 15 pg/mL across most decades
• Women: female androgen insufficiency discussion threshold approximately 0.6 to 1.0 pg/mL, though no consensus guideline has set a formal threshold [5]

The Framingham study (N=1,489 men) found that calculated free testosterone predicted sexual function and mood outcomes better than total testosterone at every age decade from the 40s through the 70s [13].

SHBG Across the Menopause Transition

Perimenopause produces erratic estradiol fluctuations that drive SHBG variability. A single SHBG measurement during the menopause transition can miss meaningful dynamics.

Early Perimenopause (Typical Age 42 to 48)

Estradiol surges above premenopausal norms are common in early perimenopause, transiently raising SHBG and suppressing free testosterone. Women reporting low libido during this phase with "normal" total testosterone and high-normal SHBG may benefit from SHBG-aware interpretation before any hormonal intervention is dismissed.

Late Perimenopause and Postmenopause

As estradiol declines persistently after the final menstrual period, SHBG tends to drift downward over 1 to 3 years, mildly increasing free testosterone relative to total. This is why some postmenopausal women report initial improvement in libido without intervention; free testosterone has quietly risen as SHBG fell. The SWAN cohort study (N=3,302 women, 10 years of follow-up) documented this SHBG trajectory and its relationship to sexual function outcomes [14].

Hormone Therapy Route and SHBG

As noted above, route of estrogen administration is the dominant modifiable factor in postmenopausal SHBG. The British Menopause Society guideline states: "Transdermal estradiol does not significantly increase SHBG, whereas oral estrogens produce a marked increase in SHBG that may reduce the bioavailability of testosterone" [15]. For women on combined estrogen-testosterone HRT, oral estrogen can create a scenario where exogenous testosterone is partially neutralized by SHBG elevation.

Factors That Modify SHBG: A Practical Reference

Understanding modifiable drivers gives clinicians and patients a non-pharmacologic toolkit.

Factors That Raise SHBG

• Oral estrogens (ethinyl estradiol, oral CEE, oral estradiol)
• Hyperthyroidism or supraphysiologic thyroid supplementation
• Phenytoin and some other anticonvulsants
• Significant caloric restriction and very low BMI
• Aging (the age-related rise is only partially modifiable)

Factors That Lower SHBG

• Insulin resistance and hyperinsulinemia
• Visceral obesity
• Hypothyroidism
• Exogenous androgens (testosterone, DHEA, danazol)
• Glucocorticoids at pharmacologic doses
• Progestins with androgenic activity (e.g., norethindrone, levonorgestrel)

A cross-sectional analysis from the NHANES III cohort (N=4,995) confirmed that fasting insulin was the strongest single predictor of SHBG in adults aged 20 to 59 after adjusting for age, sex, and BMI [16].

Clinical Decision Points: When Does an Abnormal SHBG Change Management?

Abnormal SHBG changes management when it changes the calculated free hormone result in a clinically meaningful direction, or when it points to an undiagnosed underlying condition.

Men

A man with symptoms of testosterone deficiency (fatigue, low libido, difficulty maintaining muscle, morning erection frequency decline) and:

• Total T above 300 ng/dL but SHBG above 55 nmol/L and free T below 7 pg/mL: qualifies for consideration of testosterone therapy under Endocrine Society criteria regardless of normal total T [2].
• SHBG below 15 nmol/L: warrants fasting insulin, hemoglobin A1c, liver function tests, and thyroid panel before any hormonal intervention.

Women

A postmenopausal woman on oral estrogen therapy with persistent low libido and:

• Total testosterone in mid-normal range but SHBG above 100 nmol/L: switch to transdermal estradiol before adding exogenous testosterone, as the route change alone may restore adequate free testosterone.
• SHBG below 25 nmol/L with elevated free testosterone: evaluate for polycystic ovary syndrome, adrenal hyperandrogenism, or exogenous androgen use.

The Androgen Excess and PCOS Society's 2023 position statement notes that low SHBG is one of three biochemical features required for the diagnosis of PCOS under the NIH criteria, alongside elevated total or free testosterone and evidence of ovarian dysfunction [17].

Lab Logistics: Collection, Assay Variability, and Repeat Testing

SHBG is stable in serum and does not require fasting or time-of-day standardization the way cortisol or growth hormone do. A morning blood draw is preferred for consistency when monitoring alongside testosterone, but an afternoon draw is acceptable for a standalone SHBG.

Assay Differences

Immunoassay platforms vary in their calibration. A switch between laboratory vendors can produce apparent SHBG changes of 10 to 20% without any physiologic change. The reference standard is mass spectrometry-based SHBG measurement, though this is rarely available outside research settings. When monitoring longitudinal changes, use the same laboratory and the same assay platform across timepoints.

Repeat Interval

For stable patients on no hormonal therapy, annual SHBG measurement is sufficient. Patients starting or adjusting oral estrogen, testosterone, or thyroid medication should recheck SHBG at 6 to 12 weeks after the dose change to assess the effect on free hormone fractions [2].